Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 1
1954 1
1955 1
1956 1
1957 3
1958 2
1960 2
1961 1
1962 7
1963 5
1964 6
1965 4
1966 10
1967 9
1968 7
1969 12
1970 11
1971 16
1972 7
1973 9
1974 15
1975 13
1976 14
1977 17
1978 16
1979 14
1980 17
1981 9
1982 22
1983 36
1984 24
1985 34
1986 27
1987 54
1988 55
1989 52
1990 44
1991 34
1992 41
1993 44
1994 44
1995 54
1996 52
1997 71
1998 59
1999 78
2000 93
2001 84
2002 96
2003 77
2004 84
2005 115
2006 132
2007 127
2008 153
2009 138
2010 179
2011 174
2012 190
2013 170
2014 204
2015 214
2016 199
2017 186
2018 187
2019 240
2020 257
2021 314
2022 177
Text availability
Article attribute
Article type
Publication date

Search Results

4,347 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Li BT, et al. Among authors: nakagawa k. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18. N Engl J Med. 2022. PMID: 34534430 Free PMC article. Clinical Trial.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Marabelle A, et al. Among authors: nakagawa k. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10. Lancet Oncol. 2020. PMID: 32919526 Clinical Trial.
A non-canonical vitamin K cycle is a potent ferroptosis suppressor.
Mishima E, Ito J, Wu Z, Nakamura T, Wahida A, Doll S, Tonnus W, Nepachalovich P, Eggenhofer E, Aldrovandi M, Henkelmann B, Yamada KI, Wanninger J, Zilka O, Sato E, Feederle R, Hass D, Maida A, Mourão ASD, Linkermann A, Geissler EK, Nakagawa K, Abe T, Fedorova M, Proneth B, Pratt DA, Conrad M. Mishima E, et al. Among authors: nakagawa k. Nature. 2022 Aug;608(7924):778-783. doi: 10.1038/s41586-022-05022-3. Epub 2022 Aug 3. Nature. 2022. PMID: 35922516 Free PMC article.
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆.
Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, Zhang H, Shi M, Luft A, Wolf J, Antonia S, Nakagawa K, Fairchild J, Baudelet C, Pandya D, Doshi P, Chang H, Reck M. Spigel DR, et al. Among authors: nakagawa k. Ann Oncol. 2021 May;32(5):631-641. doi: 10.1016/j.annonc.2021.01.071. Epub 2021 Feb 1. Ann Oncol. 2021. PMID: 33539946 Free article. Clinical Trial.
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Namba Y, Sumiyoshi N, Nakagawa K. Sugawara S, et al. Among authors: nakagawa k. Ann Oncol. 2021 Sep;32(9):1137-1147. doi: 10.1016/j.annonc.2021.06.004. Epub 2021 Jun 15. Ann Oncol. 2021. PMID: 34139272 Free article. Clinical Trial.
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. Piha-Paul SA, et al. Among authors: nakagawa k. Int J Cancer. 2020 Oct 15;147(8):2190-2198. doi: 10.1002/ijc.33013. Epub 2020 May 2. Int J Cancer. 2020. PMID: 32359091 Free article.
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, Haratani K, Tanizaki J, Kawakami H, Hayashi H, Sakai K, Nishio K, Nakagawa K. Suzuki S, et al. Among authors: nakagawa k. Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7. Clin Cancer Res. 2021. PMID: 34365406
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M, Yoshida T, Kumagai T, Hida T, Toyozawa R, Shimokawaji T, Goto K, Nakagawa K, Ohe Y, Seto T, Kudou K, Asato T, Zhang P, Yamamoto N. Nishio M, et al. Among authors: nakagawa k. J Thorac Oncol. 2021 Mar;16(3):452-463. doi: 10.1016/j.jtho.2020.11.004. Epub 2020 Nov 25. J Thorac Oncol. 2021. PMID: 33248320 Free article. Clinical Trial.
4,347 results